While the patient population differs between the BPH and prostate cancer risk reduction studies, the meta-analysis allows for a broader look at the effect of dutasteride on the detection of prostate cancers in patients who have a wide range of prostate-specific antigen (PSA) values, prostate volume and symptom scores, as defined by the International Prostate Symptom Score (IPSS).
What does IPSS stand for?
IPSS stands for International Prostate Symptom Score
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of IPSS
We have 117 other meanings of IPSS in our Acronym Attic
- Improved Pesticide Spray System
- In-Plane Shear Strength
- Inferior Petrosal Sinus Sampling
- Initial Preplanned Supply Support
- Instituição Particular de Solidariedade Social (Portugese: Private Social Solidarity Institution)
- Integrated Patent Search System
- International Packet Switching System (ITU-T)
- International Pilot Study of Schizophrenia
- International Professional Service Semester (Monterey Institute of International Studies; Monterey, CA)
- International Prognostic Scoring System
- Internet Protocol Security Services (Sprint)
- Internet Protocol Service Switch (Spring Tides)
- National Institute of Population and Social Security Research (Japan)
- Independent Pool & Spa Service Association, Inc.
- Indiana Public School Study Council (Ball State University)
- Integrated Program Scheduling Standard Document
- Improvements Program for Surface Ship Specified Equipments
- Ikatan Pencak Silat Seluruh Indonesia (Indonesian martial arts)
- Improved Project Scheduling and Status Reporting (Australia)
- Institute for Policy and Social Science Research (University of New Hampshire; no longer in service)
Samples in periodicals archive:
Physical examination, International Prostate Symptom Score, quality of life (QoL), five-item version of the International Index of Erectile Function (IIEF-5), basic clinical chemistry parameters, haematology, Se, testosterone, PSA (free and total), C-re-active protein (CRP), antioxidant status, transrectal ultrasound prostate volume, urinary flow rate, ultrasound-estimated post-void residual urine volume at baseline, and at 3 and 6 months, and urine ex vivo anti-adherence activity were determined in all subjects.
Questionnaires such as the International Prostate Symptom Score (IPSS) and the American Urological Association symptom index (AUA-SI) (available on www.
In phase II studies evaluating various doses, regimens, and two different formulations of cetrorelix, statistically significant differences from baseline and compared with placebo were seen on the primary end point of International Prostate Symptom Score (IPSS) at week 12.
Assessments included prostate volume (PV) by transrectal ultrasound (TRUS), maximum flow rate (Qmax) on uroflowmetry, post-void residual urine volume (PVR), International Prostate Symptom Score (IPSS), prostate specific antigen (PSA) levels, serum chemistry, and adverse events.
Recently, two long-term studies with a duration of 96 weeks and 60 weeks, respectively, were conducted and first data were presented focussing on the International Prostate Symptom Score (I-PSS), which is now recognised as the standard for assessing treatment efficacy in BPH (Roehrborn et al.